Sunday, September 13, 2026

Cellectis Eyes 2028 FDA Filing for Lasme-cel as Cash Runway Extends to Mid-2027

Cellectis plans to submit a Biologics License Application for lasme-cel to the FDA in 2028, targeting a leukemia treatment market the company projects could reach $700M in peak sales by 2035. The Paris-based biotech reported $225M in cash reserves as of September 30, 2025, funding operations into the second half of 2027. The regulatory milestone comes as Cellectis posted $62.6M in nine-month revenues, more than double the prior year period.

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Cellectis Eyes 2028 FDA Filing for Lasme-cel as Cash Runway Extends to Mid-2027
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Cellectis S.A. (NASDAQ: CLLS) anticipates filing a Biologics License Application for lasme-cel with the FDA in 2028, advancing its gene-edited CAR-T therapy toward commercialization. The company projects peak gross sales of $700M annually by 2035 across the U.S., U.K., and four major European markets, treating approximately 1,100 B-cell acute lymphoblastic leukemia patients yearly.

The clinical-stage biotech held $225M in cash and equivalents at the end of Q3 2025, down from $264M at year-end 2024. Management stated this runway extends into the second half of 2027. The cash position includes $168.2M in fixed-term deposits, with $137.6M maturing in October 2026.

Cellectis reported $62.6M in revenues for the nine months ended September 30, up from $28.8M in the same 2024 period. The increase stems primarily from collaboration activities with AstraZeneca. Third-quarter revenues alone totaled $35.2M, compared to $16.2M a year earlier.

The company narrowed its net loss to $41.3M for the nine-month period, versus $42.7M in 2024. Diluted loss per share improved to $0.41 from $0.49. Third-quarter results showed net income of $0.6M, reversing a $23.1M loss from Q3 2024.

Operating expenses held relatively flat. R&D spending declined slightly to $69.1M from $69.7M, while selling, general and administrative costs rose to $15M from $14.2M. The company attributed increased personnel costs to stock-based compensation.

Cellectis projects lasme-cel could generate up to $1.3B in peak sales if approved for expanded indications, including second-line treatment and first-line consolidation in minimal residual disease-positive patients. The allogeneic approach positions the therapy for higher margins compared to autologous CAR-T products.

The BLA filing timeline positions Cellectis for potential commercialization in 2029 or 2030, depending on FDA review duration. Manufacturing capacity exists at company facilities in Paris and Raleigh, North Carolina.

Average shares outstanding increased to 100.3M from 87.4M, reflecting equity financing activities. The company maintains partnerships with AstraZeneca and other pharmaceutical firms for its gene-editing platform.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]Press releaseGlobeNewswire· November 7, 2025
    Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com